The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: William wood - B. Riley Financial - Analyst
: I guess, maybe first off, if I could, for the extension trial, I'm just kind of curious what the rollover of patients from the induction to the maintenance
portion is, and maybe if you could provide any color on why patients may be discontinuing if so.
Question: William wood - B. Riley Financial - Analyst
: And and I assume the potential difference between placebo versus treatment isn't disclosed yet and we'll get that information more at the end.
Question: William wood - B. Riley Financial - Analyst
: Right. And then one quick last one, you, you've been saying, you're now saying 2nd quarter for the induction, I'm sorry, for the maintenance readout,
I'm just curious, I believe you were saying sort of more April, maybe even early May. Have these been, has this been now pushed out a little bit
more or you just, or relatively no changes here?
Question: William wood - B. Riley Financial - Analyst
: Yes, that makes sense. I appreciate you taking my questions. I'll hope back in Q.
Question: Gary Nachman - Raymond James Financial, Inc - Analyst
: Hey guys, good morning. This is Gary Nachman on for Gary Barnette. Just a couple of questions from us. First, talk a little bit more about your
thoughts going into the extension trial data in the 2nd quarter. What are you hoping to show and what is the bar for success, particularly on the
weight regain following the GLP-1 discontinuation? Can you remind us what your assumptions are for the placebo arm and then what are your
expectations for the enobosarm ?
And then I got another follow up.
Question: Gary Nachman - Raymond James Financial, Inc - Analyst
: Okay, great, that was super helpful. And then just another couple quick follow ups, for the safety monitoring committee that met earlier this week,
can you talk specifically about what kind of patient safety data they looked at, how far out went into? And then now that you just had a little bit
more time with the 16 week data, are you finding anything notable within the patient sites or the patient background characteristics that is abnormal
that should be called out. Thanks so much guys.
Question: Gary Nachman - Raymond James Financial, Inc - Analyst
: That's super helpful. Thanks guys, and congrats on all the progress.
Question: Dennis Ding - Jefferies - Analyst
: Good morning. This is Anthea on for Dennis. Just a couple questions from us on enobosarm. Given the oral formulation that you're working on the
new one, is there a potential for it to be combined with oral GLP 1 as a fix dose combo? I'm curious if you've looked into that and if you could pursue
a partnership on that. And then, sabizabulin's.
Colchicine, I believe works through HSCRP reduction. So can you just remind us what percent reduction they get and what the sabizabulin and
does, and given your current cash position, your confidence that phase 2 would be feasible.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 13, 2025 / 1:00PM, VERU.OQ - Q1 2025 Veru Inc Earnings Call
Thank you.
Question: Dennis Ding - Jefferies - Analyst
: Sorry, if I could ask a follow up on that, so.
What is there a numerical HSCRP reduction that's been measured for the sabizabulin or no.
Question: Dennis Ding - Jefferies - Analyst
: Right.
Question: Dennis Ding - Jefferies - Analyst
: Got it, that's really helpful.
Thank you so much.
| 
